{"entity":{"id":"nct07467863","kind":"trial","name":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","aka":[],"tldr":"A phase 1/2 trial of Dual-target CAR-NK cells in non-small-cell lung cancer, run by Beijing Biotech, now recruiting.","summary":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC is a phase 1/2 interventional study registered as NCT07467863 by Beijing Biotech, with 48 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-02-14. Interventions recorded: Dual-target CAR-NK cells and Lymphodepleting chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07467863","url":"https://clinicaltrials.gov/study/NCT07467863"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07467863","phase":"1/2","setting":"A Phase 1/2, Open-label, Biomarker-guided Study of Dual-target Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Targeting Mesothelin (MSLN) With EGFR or HER2/ERBB2, or EGFR With HER2/ERBB2, in Participants With Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)","sponsor":"Beijing Biotech","enrolled":48,"outcomes":[]},"route":"/trials/nct07467863/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}